Anticonvulsants in Hepatic Encephalopathy

  • Sona Jose St James College of Pharmaceutical Sciences (NAAC Accredited), St James Hospital Trust Pharmaceutical Research Center (DSIR Recognized) Chalakudy, Kerala.
  • Amal Roy Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India
  • N M Amala Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India
  • C S Vidhya Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India
  • Lincy George HOD, Department of Pharmaceutical Sciences, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

Abstract

Hepatic encephalopathy (HE) is a complex neurological syndrome that arises as a complication of liver dysfunction. The primary focus in HE management has traditionally been on ammonia detoxification, but recent research has paved light on the potential role of anticonvulsant medications in improving the cognitive impairment and preventing seizures associated with HE. This review mainly aims to provide a comprehensive analysis of the use of anticonvulsants in hepatic encephalopathy, by taking a looking at their mechanisms of action, efficacy, and safety profiles.


Keywords: Hepatic encephalopathy, Anticonvulsants, Cognitive impairment

Keywords: Hepatic encephalopathy, Anticonvulsants, Cognitive impairment

Downloads

Download data is not yet available.

Author Biographies

Sona Jose, St James College of Pharmaceutical Sciences (NAAC Accredited), St James Hospital Trust Pharmaceutical Research Center (DSIR Recognized) Chalakudy, Kerala.

Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

Amal Roy, Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

N M Amala, Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

C S Vidhya, Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

Pharm D, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

Lincy George, HOD, Department of Pharmaceutical Sciences, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

HOD, Department of Pharmaceutical Sciences, St. James College of Pharmaceutical Sciences, Chalakudy, Kerala 680307, India

References

1. Wijdicks E.F. Hepatic encephalopathy. N Engl J Med. 2016; 375:1660-1670. https://doi.org/10.1056/NEJMra1600561 PMid:27783916
2. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology. 2014;60:715-35. https://doi.org/10.1002/hep.27210 PMid:25042402
3. Prakash R., Mullen K.D. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010; 7: 515. https://doi.org/10.1038/nrgastro.2010.116 PMid:20703237
4. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000; 85:77-85. https://doi.org/10.1016/S0163-7258(99)00052-2 PMid:10722121
5. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009; 50:2014-2021. https://doi.org/10.1002/hep.23216 PMid:19787808
6.Zheng F, Du C, Wang X. Levetiracetam for the treatment of status epilepticus. Exp Rev Neurother. 2015; 15:1113-1121. https://doi.org/10.1586/14737175.2015.1088785 PMid:26416394
7. Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology 2018; 68:1498-1507. https://doi.org/10.1002/hep.29628 PMid:29091289
8. Prabhakar S, Bhatia R. Management of agitation and convulsions in hepatic encephalopathy. Indian J Gastroenterol. 2003 Dec;22 Suppl 2:S54-8. PMID: 150252577. Eleftheriadis N, Fourla E, Eleftheriadis D, Karlovasitou A. Status epilepticus as a manifestation of hepatic encephalopathy. Acta Neurol Scand. 2003; 107:142-4. https://doi.org/10.1034/j.1600-0404.2003.02092.x PMid:12580865
9. Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017; 77:23-36. https://doi.org/10.1016/j.pediatrneurol.2017.09.013 PMid:29097018
10. Cui B, Wei L, Sun LY, Qu W, Zeng ZG, Liu Y, Zhu ZJ. Status epilepticus as an initial manifestation of hepatic encephalopathy: A case report. World J Clin Cases 2020; 8(24):6480-6486. https://doi.org/10.12998/wjcc.v8.i24.6480 PMid:33392334 PMCid:PMC7760455
11. Hirode, G., Vittinghoff, E. & Wong, R.J. Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci 2019;64:1448-1457. https://doi.org/10.1007/s10620-019-05576-9 PMid:30863953
Crossmark
Statistics
77 Views | 8 Downloads
How to Cite
1.
Jose S, Roy A, Amala NM, Vidhya CS, George L. Anticonvulsants in Hepatic Encephalopathy. JDDT [Internet]. 15Apr.2024 [cited 12Jul.2024];14(4):108-10. Available from: https://jddtonline.info/index.php/jddt/article/view/6506